Clinical Trials in Baltimore

Showing 13481-13500 of 20,142 trials

ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not Responded to Previous Treatment

NCT00005645

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ILX-295501 in treating patients who have stage III or stage IV ovarian cancer that has not responded to previous therapy.

Fallopian Tube CancerMetastatic CancerOvarian Cancer+1 more

Genzyme, a Sanofi CompanyStarted May 1999

Los Angeles, California, United States • Indianapolis, Indiana, United States • Baltimore, Maryland, United States +5 more locations

COMPLETEDPhase 2< 1 mile

Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

NCT01270880

Hsp90 inhibitor STA-9090 may stop the growth of tumor cells by blocking some of the proteins needed for cell growth. This phase II trial is studying how well Hsp90 inhibitor STA-9090 works in treating patients with metastatic hormone-resistant prostate cancer previously treated with docetaxel-based chemotherapy

Adenocarcinoma of the ProstateHormone-resistant Prostate CancerRecurrent Prostate Cancer+1 more

Barbara Ann Karmanos Cancer Institute18 participantsStarted Jan 2011

Baltimore, Maryland, United States • Detroit, Michigan, United States • Piscataway, New Jersey, United States +1 more locations

ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not Responded to Previous Treatment

Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Find Trials by Condition in Baltimore

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors

Comprehensive HIV Prevention Package for MSM in Southern Africa: Pilot Study (Sibanye Health Project)

Pharmacokinetic and Pharmacodynamic Effects of Oral Cannabis

Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease

Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma

Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist

Rituximab to Treat Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan Anemia

Using Patients' Social Contact to Improve Out-Patient Endoscopy Among Blacks

Improving Tolerability of Bowel Preparation Laxative for Colonoscopy

Comparative Efficacy and Safety Study of GP2015 and Enbrel® in Patients With Rheumatoid Arthritis

Safety, Tolerability, and Efficacy of GS-9876 in Participants With Active Rheumatoid Arthritis on Background Therapy With Methotrexate

First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies

Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors

Aminopterin in Treating Patients With Recurrent or Refractory Endometrial Cancer

Study Evaluating HKI-272 in Tumors

Investigating Train the Trainer Delivery of Mindfulness-based Training

Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults

Safety and Dose Ranging Study of Insulin Receptor MoAb-IDS Fusion Protein in Patients With Hunter Syndrome